Next Article in Journal / Special Issue
Multilevel Impacts of Iron in the Brain: The Cross Talk between Neurophysiological Mechanisms, Cognition, and Social Behavior
Previous Article in Journal
Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell
Previous Article in Special Issue
Unraveling Hepcidin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing
Open AccessReview

Iron Deficiency as a Therapeutic Target in Cardiovascular Disease

Department of Physiology, Anatomy & Genetics, University of Oxford, Parks Road, Oxford OX1 3PT, UK
Pharmaceuticals 2019, 12(3), 125; https://doi.org/10.3390/ph12030125
Received: 10 July 2019 / Revised: 19 August 2019 / Accepted: 22 August 2019 / Published: 28 August 2019
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases)
Iron deficiency is the most common nutritional disorder in the world. It is prevalent amongst patients with cardiovascular disease, in whom it is associated with worse clinical outcomes. The benefits of iron supplementation have been established in chronic heart failure, but data on their effectiveness in other cardiovascular diseases are lacking or conflicting. Realising the potential of iron therapies in cardiovascular disease requires understanding of the mechanisms through which iron deficiency affects cardiovascular function, and the cell types in which such mechanisms operate. That understanding has been enhanced by recent insights into the roles of hepcidin and iron regulatory proteins (IRPs) in cellular iron homeostasis within cardiovascular cells. These studies identify intracellular iron deficiency within the cardiovascular tissue as an important contributor to the disease process, and present novel therapeutic strategies based on targeting the machinery of cellular iron homeostasis rather than direct iron supplementation. This review discusses these new insights and their wider implications for the treatment of cardiovascular diseases, focusing on two disease conditions: chronic heart failure and pulmonary arterial hypertension. View Full-Text
Keywords: iron; hepcidin; iron regulatory proteins; cardiomyocyte; chronic heart failure; pulmonary arterial smooth muscle cells; pulmonary arterial hypertension iron; hepcidin; iron regulatory proteins; cardiomyocyte; chronic heart failure; pulmonary arterial smooth muscle cells; pulmonary arterial hypertension
Show Figures

Figure 1

MDPI and ACS Style

Lakhal-Littleton, S. Iron Deficiency as a Therapeutic Target in Cardiovascular Disease. Pharmaceuticals 2019, 12, 125.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop